Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.
KEY POINTS
Product Offerings
The company manufactures a wide range of formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum) ointment and Oral rehydration solution (ORS).
Therapeutic Areas
Its key therapeutic areas are antibiotic, antimalarial, antidiarrheal, antituberculosis & general pain management.
Geographical Presence
The company has geographical presence across India, S.E. Asia, Africa, Brazil, South Asia, CIS, Australia and others.
Entry into Oncology Business
The company entered into oncology area by establishing its 3rd manufacturing plant in FY21. The plant will manufacture oncology products such as tablets, capsules, injectables and lyophilizers. The facility is USFDA and EU compliant.
Manufacturing Capabilities
Presently, the company owns and operates 3 manufacturing facilities; 2 in Haridwar, Uttarakhand and 1 in Bhiwadi, Rajasthan. The facilities are certified by authorities like WHO, ANVISA (Brazil), NAFDAC, MCAZ, DACA, etc.
Upgradation of Facility - In Jan 2021, the company announced partial shutdown of its Bhiwadi facility for upgradation at 3 areas of the plant.
R&D Capabilities
It has a strength of ~45 R&D employees. It has spent ~20 crores towards R&D during FY18-20 and has filed 15 patents till FY20 with various authorities.
Acquisition of Opal Pharmaceuticals
During FY20, the company acquired OPAL Pharma; an Australian pharmaceutical company and medical supplies distributor. It was acquired for ~2.3 crores INR. (420,000 AUD).
Market Cap
₹ 1,200 Cr.
Current Price
₹ 982
High / Low
₹ 999 / 390
Stock P/E
77.3
Book Value
₹ 116
Dividend Yield
0.10 %
ROCE
12.7 %
ROE
9.73 %
Face Value
₹ 10.0
KEY POINTS
Product Offerings
The company manufactures a wide range of formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum) ointment and Oral rehydration solution (ORS).
Therapeutic Areas
Its key therapeutic areas are antibiotic, antimalarial, antidiarrheal, antituberculosis & general pain management.
Geographical Presence
The company has geographical presence across India, S.E. Asia, Africa, Brazil, South Asia, CIS, Australia and others.
Entry into Oncology Business
The company entered into oncology area by establishing its 3rd manufacturing plant in FY21. The plant will manufacture oncology products such as tablets, capsules, injectables and lyophilizers. The facility is USFDA and EU compliant.
Manufacturing Capabilities
Presently, the company owns and operates 3 manufacturing facilities; 2 in Haridwar, Uttarakhand and 1 in Bhiwadi, Rajasthan. The facilities are certified by authorities like WHO, ANVISA (Brazil), NAFDAC, MCAZ, DACA, etc.
Upgradation of Facility - In Jan 2021, the company announced partial shutdown of its Bhiwadi facility for upgradation at 3 areas of the plant.
R&D Capabilities
It has a strength of ~45 R&D employees. It has spent ~20 crores towards R&D during FY18-20 and has filed 15 patents till FY20 with various authorities.
Acquisition of Opal Pharmaceuticals
During FY20, the company acquired OPAL Pharma; an Australian pharmaceutical company and medical supplies distributor. It was acquired for ~2.3 crores INR. (420,000 AUD).
Market Cap
₹ 1,200 Cr.
Current Price
₹ 982
High / Low
₹ 999 / 390
Stock P/E
77.3
Book Value
₹ 116
Dividend Yield
0.10 %
ROCE
12.7 %
ROE
9.73 %
Face Value
₹ 10.0
Commentaire:
triggered , added some units @ 880